Business Wire

NY-AQARA

8.5.2024 09:01:35 CEST | Business Wire | Press release

Share
Aqara Releases Hub M3 to Global Markets

Aqara, a leading provider of smart home products, announced the global availability of its next-generation Matter hub, the Hub M3. Designed with a focus on edge computing, the M3 prioritizes privacy and local automation capabilities that can operate independently of internet connection or even the hub itself1. Thanks to the versatile connectivity built-in, it seamlessly integrates Aqara accessories, infrared-compatible gadgets and a number of third-party Matter devices, making it a central point for smart home automation while ensuring privacy and easy setup.

“Aqara is committed to creating the ultimate smart home experience that continuously adapts to users’ evolving needs,” said Cathy You, Aqara Senior Vice President of Global Business and Strategy. “The Hub M3's edge computing capabilities will provide users with an added layer of stability and safety, while its Matter compatibility will significantly enhance interoperability and choice for users."

Debuted at CES in January, the M3 stands out as an Edge Hub by enabling not only data privacy through end-to-end encrypted, local storage but also advanced, local automation capabilities. For Aqara users who already own an Aqara Zigbee hub, deploying a Hub M3 further strengthens the robustness of their smart home networks. Moreover, it enables more local automations between Aqara devices. Once added to the network, the M3 takes a lead over other Aqara Zigbee hubs and Wi-Fi devices, and allows automation between these devices to execute on the Edge instead of over the cloud, ensures continued functionality during internet or cloud service disruptions2. The Hub M3 also allows select Aqara Zigbee devices with Repeater functionality to act as a proxy hub and execute automations in the absence of M3. Upcoming Aqara Thread devices with Mesh Extender functionality are expected to support device binding via the M3.

As the latest evolution in Aqara’s lineup of smart home control centers, the M3 supports multiple protocols including Thread, Zigbee, Wi-Fi, Bluetooth and infrared (IR), making it a comprehensive hub for smart home management. It connects and manages the lineup of classic Aqara Zigbee devices, serving as a Matter bridge3. Thanks to the 360° IR blaster, the new hub optimizes control of IR-enabled devices by syncing their status directly with Aqara Home whenever an IR remote is utilized. Moreover, the M3 integrates the latest Aqara Thread devices as well as select Matter-compatible devices from third-party brands to Aqara Home4. This means that users can connect and manage devices from different brands and ecosystems within the Aqara Home app to ensure maximum flexibility and compatibility.

Other enhancements of the Hub M3 include:

  • Matter bridge for infrared AC units: It can integrate an infrared-compatible air conditioning unit or air-to-air heat pump to Matter, allowing for AC control and automation via Matter-enabled platforms5.
  • Seamless group migration: Users can easily migrate bridged device from older Aqara hubs to the M32, ensuring continuity of Aqara Home settings and automations without the need to reconfigure each device.
  • Enhanced internet connectivity: The M3 features dual-band Wi-Fi (2.4GHz/5GHz) with WPA3 security as well as a PoE-enabled port, offering enhanced stability and flexibility.
  • Powerful speaker: The 95dB speaker built-in can be used for home security alerts and custom announcements.

The Hub M3 is now available at Aqara’s Amazon brand stores throughout North America (US, Canada), Europe (France, Germany, Italy, Poland, Spain, UK) and Asia (Japan), as well as through select Aqara retailers worldwide.

For more information on the M3, please visit our website.

1. Some Aqara Home automation may require Internet and cloud service to function, for example, automations involve push notifications and location services (e.g., geofencing, local weather, sunrise/sunset).
2. Edge automation and group migration are not supported by the original Aqara Hub and Camera Hub G2H.
3. Not all Aqara Zigbee devices can be bridged to Matter.
4. Third-party Matter device support is limited to select brands and device types by the time of M3 launch.
5. The functionality of infrared AC units may vary depending on each particular Matter-enabled platform. Each M3 hub can bridge one infrared AC unit to Matter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508489885/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye